Commentary November 22 2026

José Luis Castro | The right to breathe

6 min read

Loading article...

  • Photo - Pexels
  • Photo - Pexels
  • José Luis Castro José Luis Castro. Photo - WHO

For ten years, Revaz Vachnadze was treated for heart disease before anyone investigated his lungs. The Georgian university lecturer eventually underwent spirometry and was diagnosed with chronic obstructive pulmonary disease (COPD). By then, he had been told that ­­his lung capacity had fallen to 20-40 per cent. Climbing stairs can now trigger breathlessness and heart palpitations.

“If I had started this treatment earlier, my symptoms could have been better controlled,” he told WHO/Europe.

According to the World Health Organization, COPD caused 3.4 million deaths in 2023, making it the third leading cause of death worldwide. It ranks seventh as a cause of poor health and disability, measured in disability-adjusted life years. Nearly 90 per cent of COPD deaths among people under 70 occur in low- and middle-income countries.

His decade without a lung-function test was not caused by a missing diagnostic technology. Spirometry has long been used to confirm COPD, yet WHO notes that the test is often unavailable in low- and middle-income countries. The question for governments is why patients can still spend years in care without anyone examining their lung function.

A patient’s chance of being diagnosed and treated should not depend on whether the nearest clinic can maintain a spirometer or keep essential inhalers in stock. Yet those differences follow from public decisions about budgets, procurement, and staffing. The burden falls hardest where people have the least capacity to pay privately or travel for care.

Much of COPD’s burden remains hidden inside families. As breathlessness worsens, someone cuts back on working hours, stops visiting neighbours, and begins to depend on relatives for tasks once managed alone. Household income shrinks while unpaid care increases. Because these losses accumulate privately and gradually, they seldom command the political attention given to a visible health emergency.

The disease is also too readily dismissed as the consequence of smoking or ageing, reinforcing stigma and delaying investigation. Tobacco remains a major cause, and tobacco control is essential. But household smoke, outdoor air pollution, and occupational dust or fumes also damage lungs. Prematurity, poor lung growth before birth, childhood asthma, and serious respiratory infections can increase vulnerability decades later.

Much of this exposure is shaped by housing, income, labour protections, and local air quality. The roots of COPD often extend into policy decisions made decades before its symptoms are noticed. A child cannot choose the fuel burned at home or the conditions in which their lungs develop; a worker may have little control over the dust inhaled on a shift. Prevention, therefore, depends on clean-energy investment, enforceable air-quality standards, and workplace protections long before a person becomes a patient.

COULD MAKE A DIFFERENCE

This year’s World COPD Day, organised by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), carried the theme “Early Diagnosis and Management for a Better Life”. The campaign, held on November 18, raised a difficult question: Why do people still live with symptoms for years before receiving a test and effective treatment?

Persistent coughing, recurrent chest infections, and breathlessness with normal activity all warrant investigation. Symptoms alone cannot reliably distinguish COPD from asthma or other conditions; confirmation requires spirometry. Primary-care teams must be trained to perform and interpret the test, maintain equipment,­ and refer patients when further assessment is needed. A spirometer sitting unused in a clinic is not a diagnostic service.

An earlier diagnosis cannot reverse established lung damage, but it can bring effective care within reach before years of daily life are lost. Inhaled bronchodilators, smoking cessation support, recommended vaccinations, and pulmonary rehabilitation all have a well-established role in managing the disease. Pulmonary rehabilitation combines supervised exercise, education, and practical support, improving exercise capacity and quality of life. Exacerbations need prompt treatment and follow-up, with oxygen and specialist care when clinically indicated.

Effective treatments exist, yet many patients cannot reliably obtain them. In 2023, according to WHO, salbutamol inhalers were generally available in public primary-care facilities in fewer than two-thirds of low- and lower-middle-income countries. This is a country-level indicator for a short-acting medicine. It does not establish whether people can obtain the longer-term treatment or follow-up they need. Even so, it exposes how fragile access to basic respiratory care remains.

Continuous care means the correct medication, advice on inhaler technique, a refill the patient can afford next month, and a clinician to review worsening symptoms. Pulmonary rehabilitation must also be accessible beyond major hospitals. A diagnosis without dependable access to care may simply name symptoms that continue to worsen.

The cost of an exacerbation rarely ends at the hospital door. It may include lost wages, transport, emergency treatment,­­ and extra hours of unpaid family care, alongside the fear of another attack. Earlier diagnosis followed by sustained treatment can reduce avoidable exacerbations and help people stay active and independent.

GLOBAL RESOLUTION TO LOCAL CARE

In May 2025, the World Health Assembly adopted resolution WHA78.5, Promoting and prioritising an integrated lung health approach.

The clock for taking action is ticking, and governments are urged to connect prevention, diagnosis, and treatment across communicable and non-communicable lung diseases, including tuberculosis, pneumonia, asthma, COPD, and lung cancer.

The clinical case is straightforward: a person with a chronic cough may need investigation for tuberculosis or COPD, while another may have COPD alongside heart disease. When programmes work in isolation, patients can move from service to service without anyone taking responsibility for the whole course of care.

The resolution urges Member States, taking national circumstances into account, to integrate lung health into national policy, primary care, and universal health coverage, with effective referral pathways. Its specific provisions cover air-quality standards and monitoring, enforceable protections against occupational risks, tobacco and vaping control, vaccination, evidence-based guidance for earlier detection and treatment, and better access to affordable medicines, vaccines, and health technologies.

These responsibilities reach beyond health ministries to finance, labour, education, energy, and environmental policy. Poor respiratory health is shaped by choices made in all of these areas, and prevention cannot succeed through clinical services alone.

WHA78.5 also asked the WHO Director-General to submit an initial report for the 2027 World Health Assembly, including recommendations and consideration of a monitoring framework with measurable targets. It requests progress reports in both 2027 and 2028.

The resolution does not itself buy equipment, train staff or secure medicines. National budgets, procurement records, workforce plans and publicly reported outcomes will reveal whether governments have acted on it.

THREE PRIORITIES FOR GOVERNMENTS

1. Diagnose earlier, close to home: Train primary-care teams to recognise possible COPD and provide quality-assured spirometry, with funding for maintenance, interpretation, and referral. Report how many symptomatic patients receive timely testing, how long they wait, and where services remain unavailable. Publish results by geography and income so national averages do not conceal communities left without access.

2. Make treatment affordable and continuous: Fund dependable supplies of essential inhaled medicines and track stockouts and out-of-pocket costs. Ensure that patients have access to inhaler-technique reviews, cessation support, recommended vaccinations, pulmonary rehabilitation, and follow-up after exacerbations. Judge performance through access to these services and avoidable repeat admissions rather than simply the number of prescriptions issued.

3. Prevent exposure throughout life: Use tobacco taxes, smoke-free measures, and cessation support alongside cleaner household energy, stronger outdoor air-quality rules, and enforcement of workplace standards. Protect lung development during pregnancy and childhood, including through prevention and treatment of respiratory infections. Assign responsibilities across departments, publish exposure trends and involve people with COPD in deciding which outcomes matter.

For the next person who arrives at a clinic with persistent breathlessness, these commitments could mean a lung-function test before years pass, a diagnosis that leads to effective care and treatment that continues beyond the first prescription. The difference is felt in the freedom to work, visit friends, manage daily tasks and remain part of family life.

Revaz cannot recover the decade before his lungs were assessed. Governments can prevent others from losing the same years. WHA78.5 must be judged by what changes for people: fewer avoidable admissions, more reliable access to treatment, less harmful exposure, and a fairer chance of care regardless of income or place of birth.

The test of the right to breathe is whether fewer people are left to ask, after years of breathlessness, why nobody checked their lungs sooner.

We must not forget that governments are responsible for giving that right meaning in everyday life.

José Luis Castro is the WHO Director-General’s Special Envoy for Chronic Respiratory Diseases. Send feedback to columns@gleanerjm.com